Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics and Pharmacokinetics of Subcutaneous NNC0363-1063 in Type 1 Diabetes
NCT07305805Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of NNC0363-1063 in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the glucose infusion rate-time curve at steady state at Day 3. Started Dec 2025; status: completed.
02
Drugs
NNC0363-1063
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07305805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07305805.